We have characterized a new mutant mouse that
Introduction
f3-Glucuronidase (#-D-glucuronide glucuronohydrolase EC 3.2.1.31) is a lysosomal enzyme expressed in most, if not all, mammalian tissues (1) . In mouse kidney and liver the enzyme is also found in the microsomes in association with the accessory binding protein, egasyn (2) . The active enzyme is a tetrameric glycoprotein that degrades glycosaminoglycans by removing fl-glucuronosyl residues at the nonreducing end of oligosaccharides (3, 4) . Severe deficiency ofthis enzyme results in the accumulation of undegraded glycosaminoglycans in the lysosomes and produces the disease mucopolysaccharidosis type VII (5) . This disease was first described in humans (6, 7) but there is also a canine model of fl-glucuronidase deficiency (8) .
Murine #-glucuronidase has been studied extensively because it provides a useful system for understanding mammalian gene regulation (1) . The structural gene, Gus-s, is located on the distal half of chromosome 5 of the mouse. There are three common alleles designated Gus-sa, Gus-sb, and Gus-s/? which are differentiated by electrophoretic mobility and heat Receivedfor publication 13 September 1988. stability (9-1 1). Three regulatory elements, designated Gus-r, Gus-t, and Gus-u, are closely linked to Gus-s. Gus-r is cis-acting and determines the level of Gus-s mRNA in the proximal tubule cells of the kidney in response to androgen induction (12) . Gus-t is a trans-acting temporal regulator that determines the rate of 3-glucuronidase synthesis in several mouse tissues during postnatal development (13, 14) . Gus-u is a systemic cis-acting regulator that determines the relative levels of enzyme activity in all tissues (14, 15) . These three regulatory elements in conjunction with the structural gene define the f3-glucuronidase gene complex, [Gus] .
In C3H strains of mice which are of the [GusIH haplotype (16) , there are relatively low levels of fl-glucuronidase activity in all tissues but the mice do not have any clinical symptoms. In lieu of a better mouse model, C3H mice have been utilized to study the correction of lysosomal enzyme deficiency by allogeneic bone marrow transplantation (17) . Several years ago, three mice with dwarfing characterized by shortness of nose, limbs, tail, and body length were identified in a colony of B6.C-H-2bmJ mice at The Jackson Laboratory. The mutant gene was given the provisional name of adipose storage deficiency (asd) because, in addition to the obvious skeletal deformities, the animals were devoid of visually identifiable white adipose tissue (18) . While studying this mutation at the genetic and biochemical levels, we found that the mutation is closely linked to the Gussb allele and causes a severe, if not complete, deficiency of /-glucuronidase activity. Because this mutant mouse has a disease resembling human mucopolysaccharidosis type VII (MPS VII),' we have renamed the recessive mutation gusmPs. This paper describes our initial characterization of this mutation at the genetic, cellular, biochemical, and molecular levels. The results show that the mutation causes a severe lysosomal storage disease that we have named murine MPS VII. In addition, we discuss the importance ofthis mouse in developing methods of therapy for lysosomal storage diseases as well as providing information about the regulation of mammalian gene expression.
Methods
Animals. All animals used in these studies were from The Jackson Laboratory. They were obtained from the B6.C-H-2bm`/ByBir-gusmPs/+ mutant strain maintained in the research colony of Dr. Birkenmeier, from the MOR/Rk strain maintained by T. H. Roderick, and from the DBA/2J production colony of The Jackson Laboratory. The mutant strain was maintained by brother-sister matings of gusPs/+ animals and each animal was assigned a pedigree number that was recorded in the breeding records. The mice were fed Wayne Sterilizable Rodent Blox (Continental Grain Company, Chicago, IL), which is essential for the optimal health and reproductive performance ofthe mutant strain.
Transmission electron microscopy. Tissues were fixed in 2% glutaraldehyde, 1% paraformaldehyde in 0. RNA isolation and characterization. Total cellular RNA was isolated from mouse tissues by extraction with guanidine thiocyanate followed by centrifugation through CsCl (24) . Poly A' RNA was isolated using oligo-dT cellulose chromatography. Northern blots were prepared after formaldehyde-agarose gel electrophoresis of the RNA (25) . The Zetabind (AMF, Meriden, CT) nylon filters were hybridized to cDNA probes radiolabeled by the random hexamer method as described previously (26, 27) .
For the SI nuclease protection assays, part of the pGUS-l cDNA clone representing exons 2 through 12 was subcloned into a Blue Scribe vector (Stratagene, LaJolla, CA). T7 RNA polymerase was used with [32P]UTP to make labeled anti-sense RNA (cRNA) that was separated from the template by agarose gel electrophoresis. For each assay 100 ,g of total RNA was suspended in a formamide hybridization buffer containing 1-5 X I05 cpm ofthe cRNA probe. The sample was denatured at 85°C and then allowed to hybridize at 65°C from 3 h to overnight. After hybridization, the samples were treated with 400 U S1 nuclease. To assay for the SI -resistant hybrid molecules, the samples were electrophoresed in nondenaturing polyacrylamide gels. The gels were dried and autoradiography performed at -70°C with an intensifying screen. To confirm that equal amounts of RNA were present in each assay, parallel assays were performed using a y-actin cRNA probe. An additional control assay utilized Escherichia coli RNA rather than mouse tissue RNA in the hybridization reaction in order to verify the specificity of the bands detected.
Southern blot analysis. Genomic DNAs were digested with restriction enzymes, electrophoresed in 0.8% agarose gels, and transferred to Zetabind nylon filters by the Southern method (28) . Probes were made from the various cloned DNAs using the random hexamer labeling method and were hybridized to the nylon filters as described previously (26 Molecular clones. The cloned DNAs used to make probes for the Northern and Southern blots were obtained from several sources. The pGUS-l cDNA clone of murine fl-glucuronidase (12) was obtained from Dr. Ganschow. The subclones from the cosmid clone D23 (or PGY-1) of the Gus-sb allele from the YBR mouse strain (30) were provided by K. Paigen (University of California, Berkeley, CA). The a-fetoprotein cDNA clone, pHcII 440, was obtained from S. M. Tilghman (Princeton University, Princeton, NJ).
Results
History and clinical description of the gus1P1mgusPS mouse.
The mutation occurred on the congenic mouse strain B6.C-H-2b'/By, which was originally called H(z 1). This strain carries a mutant H-2Kb allele named H-2Kbml. The strain originated from a C57BL/6By female mated to an irradiated BALB/cBy male (31) . The H-2Kbml mutation was backcrossed for 10 generations to C57BL/6By mice and then inbred in order to establish the congenic strain mentioned above. Approximately 10 yr later in 1976, the first gusmPs/gusmPs animals were identified in the B6.C-H-2bm'/By colony at generation F34. The parents and their offspring were used to develop a separate inbred colony of mice maintained by strict brothersister matings of pedigreed animals. Mutant males are reproductively sterile for reasons independent of gonadal and reproductive tract morphology or of sperm number, morphology, and motility. Mutant females are capable of producing litters but, because of insufficient lactation, the offspring must be raised by foster mothers. Therefore, the strain, named B6.C-H-2bmI/ByBir-gusmPsI+, is maintained by mating heterozygous gusrPs/+ siblings identified by their ability to produce mutant offspring. olization present in endothelial cells of spleen and liver. These findings are remarkably similar to human patients with fl-glucuronidase deficiency (6, 22) . However, the specific diagnosis of murine MPS VII required the genetic and biochemical data presented below. These results suggested that guSr'Ps was located on the distal half of chromosome 5. This was confirmed using an intercross with MOR/Rk mice. MOR mice carry the Mor-lb and Gus-sa alleles, while the mutant strain carries the Mor-Ja and GUSSb alleles (20) . The gene order on chromosome 5 is Pgm-J, Afp, f3-glucuronidase (Gus), and mitochondrial malate dehydrogenase (Mor-J). Among 74 mutant animals typed for Mor-J, there was 6.08±1.96% recombination between gusmPs and Mor-J. To complete the genetic studies, the mutation was mapped to the [Gus] complex using a f3-glucuronidase cDNA clone, pGUS-1, that detects a Hind III RFLP between the structural genes Gus-sa and GUSSb (16) . Out of 40 DNAs tested (80 chromosomes), no recombination occurred between gusmPs and GUSSb. Thus, at the 95% upper confidence limit, these two loci are located within 3.7 centimorgans of one another. In addition, these results showed that the congenic strain carrying the gusmPs mutation had the C57BL/6By Gus5b allele rather than the BALB/cBy Gus-sa allele. Therefore, the radiation treatment given the original BALB/cBy father of the H(zl) mouse could not have been the direct cause of the gusmPs mutation. In all probability, gusPs is a spontaneous mutation of the [GUS]B haplotype that occurred in the B6.C-H-2bm'/By colony.
Biochemical characterization ofgusmPs/gusmPs mice. While the chromosome mapping studies were in progress, we attempted to biochemically type the mutant mice for the two f3-glucuronidase alleles present in the second intercross. However, when the cellulose acetate plates were stained for ,B-glucuronidase activity by a simultaneous dye coupling method using naphthol-AS-BI-f3-D-glucuronide as substrate (l1), no activity was observed. This finding indicated that the biochemical defect was probably f3-glucuronidase deficiency. To measure more accurately the specific activity ofB-glucuronidase in various tissues, we used a sensitive fluorometric assay with 4-methylumbelliferyl-,3-D-glucuronide as the substrate (21, 22 Fig. 4 shows that the gusrPs/+ parents producing mutant offspring had levels of activity in liver that were approximately one-half of that observed in C57BL/6J mice. In Kidney p-Glucuronldase mRNA Levels
[Gus]a (30) . With all three enzymes, the mutant allele looked identical to the normal allele (data not shown). The pGUS-l cDNA clone also failed to detect any differences between the normal and mutant DNAs. Therefore, Southern blot analysis did not reveal any large deletions, duplications, insertions, or rearrangements within a 35-kb segment of the mutant genome that contains the Gus structural gene. Either the mutation has not generated a RFLP that is detectable with the three restriction enzymes we tested or the mutation is located outside of the region covered by our probes.
Because methylation of specific DNA sequences sometimes correlates with levels of expression of certain genes, we used the methylation-sensitive enzyme, Hpa II, to determine the methylation status of some of the cytosine residues within the mutant Gus locus. Liver DNA from the mice used in the Southern blots described above, was digested with either Hpa II or the methylation-insensitive isoschizomer, Msp I. The DNAs were Southern blotted and hybridized to the pGUS-1 cDNA probe and the results are shown in Fig. 7 . The mutant and normal DNAs looked identical when digested with Msp I and three major bands were resolved in the gel. The Hpa II digests were different from the Msp I digests, and at least six easily discernible bands were present in each lane. However, the Hpa II digests of all three DNAs were essentially identical to one another. These results indicate that methylation of cytosine residues has occurred at some of the Msp I sites in liver DNA, and that the sites which are methylated are identical in normal and mutant animals.
Discussion
This article describes a recently discovered mutant mouse at the genetic, cellular, biochemical, and molecular levels. The data show that the phenotype and clinical presentation of the disease in this mouse can be attributed to the lack of,-glucuronidase activity in the various tissues tested. We concluded 13 that the mouse has a lysosomal storage disease that is the murine counterpart of a human disease, mucopolysaccharidosis type VII (MPS VII), described originally in a patient by William S. Sly and colleagues (6) . Since this original article, there have been 19 patients reported in the literature (33) .
There is also a single report of f3-glucuronidase deficiency in a dog (8) . Although there are inbred strains of mice with high and low levels of f-glucuronidase activity, none have a severe enough deficiency to cause a disease with similarities to human MPS VII (15, 17) . Therefore, as a null mutation, the gusmPs/gusmPs mouse is a unique resource that will have a broad application in answering many important scientific questions about (a) fl-glucuronidase-deficient mucopolysaccharidosis and (b) regulation of Gus gene expression. enzyme deficiency will require that the mutation be defined at the DNA sequence level. One likely possibility is that the DNA sequence of the promoter or an associated regulatory element such as an enhancer has been altered in the mutant. Alternatively, the promoter may be capable of functioning normally as suggested by the testosterone induction experiment. The mRNA species observed on the Northern blots are consistent with the possibility that the defect is related to mRNA stability or processing. Whatever the cause of this mutation, further study of the genetic defect at the molecular level will lead to a better understanding of the regulation of f3-glucuronidase gene expression.
It is also important to recognize the usefulness of this null mutation in providing a genetic background in which to study certain cellular processes. Lysosomes are involved in many cellular processes including killing infectious agents, degradation of hormones and transport proteins, turnover of intracellular proteins, and remodeling of tissues and bones. Crucial to appropriate lysosomal function is the trafficking of lysosomal enzymes (34) . Thus, in addition to understanding the biological consequences of lysosomal enzyme deficiencies, it is necessary to understand the mechanisms responsible for normal lysosomal enzyme synthesis, sorting, and transport. It is now technically possible to make transgenic mice carrying either various naturally occurring Gus structural alleles or in vitro mutated f3-glucuronidase coding sequences. If these transgenes are then placed on the gusmPs/gusmPS genetic background by appropriate genetic crosses, it should provide a valuable biological system in which to identify and characterize the molecular signals required for correct cellular processing and targeting of lysosomal enzymes.
In the area of clinical investigation, research on murine MPS VII may have important implications. Human MPS VII has been reported to have considerable phenotypic variation (33, 35) . It is unclear which of the various symptoms and their severity relate directly to enzyme deficiency and which are also affected by genetic background and other disease processes. The murine gusmPs mutation is on a well-defined homogeneous genetic background. All of the mice are pedigreed and the colony has been maintained by strict brother-sister matings. Thus, the gusmP11gusmPs mouse offers a model system in which to study the pathogenesis of a lysosomal storage disease in a large number of animals with a uniform genetic background. Although MPS VII is a rare disease, all of the human lysosomal storage diseases taken together have a significant clinical incidence. Studies using animal models of the human diseases may provide important information about the clinical course of the disorder and suggest ways to treat humans with similar lysosomal enzyme defects (17, 36) . Two interesting possibilities for treatment of murine MPS VII are transplanta-tion of normal syngeneic bone marrow cells and infection of mutant bone marrow stem cells with defective retroviruses that encode murine or human 3-glucuronidase. Our preliminary results with bone marrow transplantation into sublethally irradiated (200-400 rads) mutant mice have shown remarkable reversal of storage disease pathology in many tissues. To date, 78% (14/18) of the animals that received transplants are still alive and are between 400 and 500 d of age (Birkenmeier et al., unpublished results). We predict that some may approach a normal lifespan and reach an age of at least 2 yr.
In summary, we have identified a murine lysosomal storage disease that has many similarities to human MPS VII.
There is little if any fl-glucuronidase activity present in these mice because of a very low level of f3-glucuronidase mRNA.
The exact nature of the defect at the DNA level has yet to be defined but the gus nPs mutation maps to the [Gus] complex on chromosome 5. The mice may be useful in further basic research involving regulation of gene expression and trafficking of lysosomal enzymes as well as clinical research involving lysosomal storage diseases and their treatment.
